CAR-P Diem

Fighting cancer cachexia with engineered macrophages.

Percentage of late-stage cancer patients with cachexia

Percentage of cancer deaths directly caused by cachexia

Number of FDA-approved treatments for cachexia

Cancer cachexia

Cancer cachexia is a wasting syndrome experienced by 80% of advanced-stage cancer patients that induces significant muscle and fat loss and directly causes approximately 30% of cancer deaths1. Despite its devastating effect on patient outcomes, there are currently no FDA-approved treatments for cancer cachexia2.

CAR-P Diem

Our project tackles cachexia through engineered macrophages that modulate the levels of interleukin-6 (IL-6), a cytokine whose overabundance in cancer patients causes systemic immune dysfunction and is largely responsible for the wasting associated with cachexia3. By engineering macrophages with a chimeric antigen receptor that induces phagocytosis upon IL-6 binding, we have designed a novel therapeutic that reduces IL-6 levels to a healthy baseline.

CAR-P Diem alleviates symptoms of cachexia, helping cancer patients regain control over their health, fight cancer, and seize the day!

To quickly learn more about our project, view our project promotion video below.


  1. “Treating Cancer Cachexia: Progress Looks Possible.” National Cancer Institute, Accessed 29 June 2023.
  2. Roeland, Eric J., et al. “Management of Cancer Cachexia: ASCO Guideline.” Journal of Clinical Oncology, vol. 38, no. 21, 2020, pp. 2438–2453,
  3. Narsale, Aditi A., and James A. Carson. “Role of Interleukin-6 in Cachexia.” Current Opinion in Supportive & Palliative Care, vol. 8, no. 4, 2014, pp. 321–327,